Linkster is a swiss-based precision medicine company focusing on multi-specific antibodies and tissue-specific delivery. The company creates next generation targeted therapeutics through its Flycode® platform for high-throughput cellular and in vivo antibody engineering.
Linkster has entered into several agreements with pharmaceutical and biotech companies and is actively seeking further partnerships for the co-development of innovative therapeutic products.
For more information, please visit https://linkstertx.com
Company Details
- Employees
- 5
- Founded
- -
- Address
- Gloriastrasse 28/30, Zürich,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://linkstertx.com
- Keywords
- Antibody precision medicines engineered In Vivo, High-throughput pharmacokinetics & biodistribution, Novel Sybody/Nanobody platform technology.
- HQ
- Zürich
Linkster Therapeutics Questions
Linkster Therapeutics's website is https://linkstertx.com
Linkster Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/linkstertx
Linkster Therapeutics has
5 employees.
View email and phone details for 5
employees at Linkster Therapeutics.
Linkster Therapeutics's industry is
Biotechnology Research
Linkster Therapeutics's top competitors are
Endogena Therapeutics, Inc.,
Araris Biotech Ag,
Athebio Ag,
Dinaqor,
Metriopharm,
Memo Therapeutics Ag,
Juvabis Ag,
Novago Therapeutics,
Molecular Partners,
Biognosys.
Linkster Therapeutics's categories are Biotechnology Research
Linkster Therapeutics's founding year is 2019
